SERA logo

SERA PROGNOSTICS INC-A

SERANASDAQ
🏆 #4069 by market capUS Equity
$2.07▲ $0.00 (+0.00%)
Latest quote
🔔
Track SERA
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.0%
7d▲ 0.0%
14d▲ 1.2%
30d▼ 0.2%
ytd▼ 28.3%
1y▼ 39.8%
🏦Market Cap
$81M
Small Cap
📈Revenue Growth (YoY)
-35.2%
Declining
📊Gross Margin
-150.0%
Thin
💵FCF Margin
—
⚖️P/S Ratio
1155.3x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.06 – $2.06
52-Week Range
$1.56 – $3.95
Volume (shares)
361
Avg Volume (shares)
—
Shares Outstanding
39.5M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$81,000
Last Q Revenue
$30,000
P/E Ratio
—
P/S Ratio
1155.3x
EPS (TTM)
$-0.66
Dividend Yield
—
Dilution (1yr)
+47.3%
SERA logo

SERA PROGNOSTICS INC-A

SERA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$81K▲ +5.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-102.5%▲ +1478.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$37M▼ −0.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$26M▲ +72.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
50.0M▲ +47.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$2M YoY
StockOtter · stockotter.space

About SERA PROGNOSTICS INC-A

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.